Suchergebnisse - "Van Cutsem, E"

PubPharm (33)

1

MODUL cohort 2 : an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer

enthalten in: ESMO open | 2022

von Tabernero, J. | Grothey, A. | Arnold, D. | +8

2

Bevacizumab as adjuvant treatment of colon cancer : updated results from the S-AVANT phase III study by the GERCOR Group

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von André, T. | Vernerey, D. | Im, S. | +18

3

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment : results of an ACCENT pooled analysis of seven studies

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Taieb, J. | Shi, Q. | Pederson, L. | +12

CommentIn: Ann Oncol. 2019 Sep 1;30(9):1409-1410. - PMID 31350557

4

Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Yoshino, T. | Portnoy, D. | Obermannová, R. | +19

5

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

6

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Taieb, J. | Balogoun, R. | Le Malicot, K. | +18

7

Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Obermannová, R. | Van Cutsem, E. | Yoshino, T. | +14

8

FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer : A retrospective subgroup analysis of the CRYSTAL study

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2016

von Köhne, C. | Poston, G. | Folprecht, G. | +4

9

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Van Cutsem, E. | Prenen, H. | D'Haens, G. | +11

10

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Macarulla, T. | Cervantes, A. | Tabernero, J. | +10